Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Operating Income (2016 - 2025)

Viking Therapeutics' Operating Income history spans 12 years, with the latest figure at -$164.7 million for Q4 2025.

  • For Q4 2025, Operating Income fell 256.28% year-over-year to -$164.7 million; the TTM value through Dec 2025 reached -$393.3 million, down 160.63%, while the annual FY2025 figure was -$393.3 million, 160.63% down from the prior year.
  • Operating Income for Q4 2025 was -$164.7 million at Viking Therapeutics, down from -$98.6 million in the prior quarter.
  • Across five years, Operating Income topped out at -$12.5 million in Q4 2021 and bottomed at -$164.7 million in Q4 2025.
  • The 5-year median for Operating Income is -$25.5 million (2023), against an average of -$38.6 million.
  • The largest annual shift saw Operating Income dropped 11.04% in 2021 before it crashed 256.28% in 2025.
  • A 5-year view of Operating Income shows it stood at -$12.5 million in 2021, then plummeted by 62.13% to -$20.3 million in 2022, then crashed by 44.38% to -$29.3 million in 2023, then plummeted by 57.89% to -$46.2 million in 2024, then plummeted by 256.28% to -$164.7 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Operating Income are -$164.7 million (Q4 2025), -$98.6 million (Q3 2025), and -$74.6 million (Q2 2025).